Core Points - The company announced the completion of the cancellation of certain stock options and the repurchase of restricted stocks as part of its 2022 incentive plan [2][3] - A total of 1,238,500 stock options will be canceled due to the departure, retirement, or demotion of certain incentive recipients [2] - The cancellation will not affect the company's capital structure or the ongoing implementation of the 2022 incentive plan [3] Summary by Sections - **Incentive Plan Details** - The company held meetings on July 22, 2024, and April 25, 2025, to approve the cancellation of stock options and repurchase of restricted stocks [2] - The canceled stock options include 869,000 from the initial grant, 279,500 from the first reserved grant, and 90,000 from the second reserved grant [2] - **Regulatory Compliance** - The company submitted the cancellation application to the China Securities Depository and Clearing Corporation Shanghai Branch, which confirmed the completion of the cancellation on August 6, 2025 [2] - **Impact Assessment** - The cancellation of stock options will not impact the company's capital structure or the continuation of the incentive plan [3]

证券代码：600566 证券简称：济川药业 公告编号： 2025-062 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分股票期权注销完成的公告 本次股票期权注销事宜不会影响公司的股本结构，亦不会影响公司 2022 年 限制性股票与股票期权激励计划的继续实施。 特此公告。 湖北济川药业股份有限公司董事会 2025 年 8 月 8 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据湖北济川药业股份有限公司（以下简称"公司"）2022 年第二次临时 股东大会的授权，公司于 2024 年 7 月 22 日、2025 年 4 月 25 日，分别召开第十 届董事会第十次会议和第十届董事会第十四次会议，审议通过了《关于注销部分 股票期权并回购注销部分限制性股票的议案》：由于部分激励对象离职、退休， 发生降职、降级，根据《湖北济川药业股份有限公司 2022 年限制性股票与股票 期权激励计划》（以下简称"本激励计划"）的相关规定，公司拟注销上述激励 对象已获授但尚未行权的股票期权合计 123.85 万份（其 ...

Core Insights - As of August 6, a total of 117 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest streak of net financing inflows are Chengdi Xiangjiang and Huicheng Environmental Protection, both achieving 18 consecutive trading days of net inflows [1] - Other notable stocks with significant net financing inflows include Juhe Materials (15 days), China Baoan (12 days), Jiuri New Materials, New Mileage, Jichuan Pharmaceutical, Cangge Mining, Tianzhihang, and Zhejiang Jiaoke, each with 10 to 11 consecutive trading days of net inflows [1]

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Hubei Jichuan Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the cancellation of certain stock options and the repurchase of restricted stocks, in accordance with relevant laws and regulations [2][12]. Group 1: Approval and Authorization - The company held multiple board meetings and a shareholders' meeting in 2022 and 2023 to approve the incentive plan and related matters, with independent directors providing their consent [5][6][7]. - The legal opinion states that the company has complied with the necessary legal requirements and has conducted thorough verification of the facts and legal issues related to the incentive plan [3][4]. Group 2: Details of Cancellation and Repurchase - The company plans to cancel a total of 264,000 stock options and repurchase 219,000 restricted stocks due to the departure of 9 incentive recipients, and an additional 318,500 stock options and restricted stocks due to the demotion of 22 recipients [9][10]. - The repurchase price for the restricted stocks will be based on the grant price plus interest from the People's Bank of China, with specific prices set for different batches of stocks [10]. Group 3: Funding and Disclosure - The funding for the repurchase will come from the company's own funds, and a dedicated securities account has been established for this purpose [10]. - The company has fulfilled its obligation to disclose information regarding the repurchase and cancellation, with announcements made in accordance with regulatory requirements [11][12].

公司于 2025 年 4 月 25 日召开第十届董事会第十四次会议，审议通过了《关 于注销部分股票期权并回购注销部分限制性股票的议案》：鉴于 14 名激励对象 离职、1 名激励对象退休，根据本激励计划的相关规定，公司拟注销上述激励对 象已获授但尚未行权的股票期权 65.6 万份(其中首次授予股票期权数量 35.8 万 份，预留授予（第一批）股票期权数量 25.3 万份，预留授予（第二批）股票期 权数量 4.5 万份)，拟回购注销上述激励对象已获授但尚未解除限售的限制性股 票 50.6 万股(首次授予限制性股票数量 20.8 万股，预留授予(第一批)限制性股 票数量 25.3 万股，预留授予(第二批)限制性股票数量 4.5 万股)。 证券代码：600566 证券简称：济川药业 公告编号： 2025-061 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?回购注销原因：湖北济川药业股份有限公司（以下简称"公 ...

Core Insights - As of August 5, a total of 116 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest consecutive net inflow days are Huicheng Environmental Protection and Chengdi Xiangjiang, both achieving 17 consecutive trading days of net inflows [1] - Other notable stocks with significant consecutive net inflow days include Gaomei Co., Juhe Materials, China Baoan, Langkun Technology, Jichuan Pharmaceutical, Jiuri New Materials, Xinlicheng, Cangge Mining, Tianzhihang, and Jingcheng Co., with inflow days ranging from 9 to 15 [1]

Group 1 - A total of 107 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for 5 consecutive days or more as of August 4 [1] - The stocks with the longest consecutive net inflows are Chengdi Xiangjiang and Huicheng Environmental Protection, both achieving 16 consecutive trading days of net inflows [1] - Other notable stocks with significant consecutive net inflows include Gaocai Co., Ltd. (14 days), Juhe Materials (13 days), Juchen Co., Ltd. (12 days), China Baoan (10 days), Hongrun Construction (9 days), Jiurichuang New Materials (9 days), New Mileage (9 days), Jichuan Pharmaceutical (9 days), and Langkun Technology (9 days) [1]

人民财讯8月1日电，企查查APP显示，近日，济嘉(海南)医学科技有限公司成立，法定代表人为曹伟， 注册资本为1亿元，经营范围包含：药物临床试验服务；药品生产；药品批发；生物基材料聚合技术研 发；企业管理咨询；市场营销策划等。企查查股权穿透显示，该公司由济川药业（600566）间接全资持 股。 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]